IMCR vs. RVMD, ASND, CYTK, VKTX, BBIO, BPMC, OGN, NUVL, KRYS, and RARE
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Revolution Medicines (RVMD), Ascendis Pharma A/S (ASND), Cytokinetics (CYTK), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Organon & Co. (OGN), Nuvalent (NUVL), Krystal Biotech (KRYS), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.
Revolution Medicines (NASDAQ:RVMD) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.
Immunocore has higher revenue and earnings than Revolution Medicines. Immunocore is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
Revolution Medicines currently has a consensus price target of $52.92, indicating a potential upside of 26.47%. Immunocore has a consensus price target of $80.70, indicating a potential upside of 141.62%. Given Immunocore's higher probable upside, analysts clearly believe Immunocore is more favorable than Revolution Medicines.
In the previous week, Immunocore had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 5 mentions for Immunocore and 3 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.86 beat Immunocore's score of 0.63 indicating that Revolution Medicines is being referred to more favorably in the media.
Revolution Medicines has a net margin of 0.00% compared to Immunocore's net margin of -19.16%. Immunocore's return on equity of -14.68% beat Revolution Medicines' return on equity.
94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 8.0% of Revolution Medicines shares are owned by insiders. Comparatively, 9.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Revolution Medicines has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
Revolution Medicines received 18 more outperform votes than Immunocore when rated by MarketBeat users. However, 74.36% of users gave Immunocore an outperform vote while only 72.38% of users gave Revolution Medicines an outperform vote.
Summary
Revolution Medicines and Immunocore tied by winning 9 of the 18 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
Free IMCR Stock Alerts